Immortalized Mesenchymal Stem Cells: A Safe Cell Source for Cellular or Cell Membrane-Based Treatment of Glioma

Figure 7

(a)–(c) Cellular uptake of PM and expression of tumor-homing molecules. (d)–(e) Biodistribution of im-MSCs PM after intravenous (IV) injections. (a) IF staining of ATP1A1 (red) in U87 and U251, PM marked with DIO (green), magnification, ×200. Scale bar, 50 μm. (b) Flow cytometry showing the uptake curve of MSC-PM by U87 and U251. (c) Real-time reverse transcription-PCR (RT-PCR) detection of CXCR4 and SELPLG mRNA expression in hADSCs and im-hADSCs of different PDs. The results are presented as the mean ± SD of biological triplicate assays. . (d) Representative IVIS luminescence imaging at different time points (0.5 hours, 2 hours, 6 hours, 12 hours, 24 hours, 48 hours, and 72 hours) after mice bearing gliomas were injected with cell membranes (im-hUCMSC-PM or RBC-PM). (e) The fluorescence signal intensity of the mice. The results are presented as the mean ± SD of biological triplicate assays. , , . ns: not significant. IF: immunofluorescence; PD: population doubling.

(a)

(b)

(c)

(d)

(e)